Tuesday, September 23, 2025 3:42:16 AM
Yes, I've considered that many times. Not only would NWBO's inability to provide requested patient level data render such an RFI a material event, but the MHRA would NEVER allow for an RFI to sit unanswered for over a year because there are LAWS about the amount of time every company has to respond to an RFI.
IMO is much more likely that the MHRA and NWBO are "working together/actively engaged" as both the parties have repeatedly stated in writing. Combined with the legislative backdrop and the company's acquisition of Advent for pennies on the dollar and accompanying written statements implying that approval and substantial scale up in manufacturing are the reasons for the acquisition, my wee brain tells me that the approval you call a "miracle" is far more likely than not.
No matter how many times that you repeat the "regulatory stealth rejection" theory, it remains one of the least likely bearish theories and really makes the time you spend here 24/7/365 seem more like paid FUD than altruism... but you already knew that.
IMO is much more likely that the MHRA and NWBO are "working together/actively engaged" as both the parties have repeatedly stated in writing. Combined with the legislative backdrop and the company's acquisition of Advent for pennies on the dollar and accompanying written statements implying that approval and substantial scale up in manufacturing are the reasons for the acquisition, my wee brain tells me that the approval you call a "miracle" is far more likely than not.
No matter how many times that you repeat the "regulatory stealth rejection" theory, it remains one of the least likely bearish theories and really makes the time you spend here 24/7/365 seem more like paid FUD than altruism... but you already knew that.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
